Floatz logo

Therapeutic Asset Ratings

427 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
ETOPOSIDE
Prostate Cancer
University of WashingtonP3B (61)
Ipilimumab
Prostate Cancer
Australian and New Zealand Urogenital and Prostate Cancer Trials GroupP3B (61)
ly01005
Prostate Cancer
The First Affiliated Hospital of Xiamen UniversityP3B (61)
Tislelizumab
Prostate Cancer
Shanghai Changzheng HospitalP3B (61)
Durvalumab
Prostate Cancer
OHSU Knight Cancer InstituteP2B (61)
Eloxatin
Prostate Cancer
Parabilis Medicines, Inc.P2B (61)
Decapeptyl
Prostate Cancer
Cancer Research AntwerpP4B (60)
Letrozole
Prostate Cancer
Case Comprehensive Cancer CenterP4B (60)
MIDAZOLAM
Prostate Cancer
The Netherlands Cancer InstituteP4B (60)
NEPENTHE
Prostate Cancer
University Hospital of North NorwayP4B (60)
ROPIVACAINE
Prostate Cancer
Memorial Sloan Kettering Cancer CenterP4B (60)
Trimethoprim
Prostate Cancer
University of California, San DiegoP4B (60)
BUSERELIN
Prostate Cancer
NRG OncologyP3B (60)
CIS-DIAMMINEDICHLOROPLATINUM II
Prostate Cancer
The First Affiliated Hospital of Xiamen UniversityP3B (60)
PADELIPORFIN
Prostate Cancer
Steba Biotech S.A.P3B (60)
RADIUM RA-223
Prostate Cancer
University of California, San FranciscoP3B (60)
Solu-Cortef
Prostate Cancer
National Cancer Institute (NCI)P3B (60)
Gm-Csf
Prostate Cancer
University of Wisconsin, MadisonP2B (60)
Tranexamic Acid
Prostate Cancer
Konkuk University Medical CenterP4B (59)
Nivolumab
Prostate Cancer
ExelixisP3B (59)
68ga-psma
Prostate Cancer
The First Affiliated Hospital of Anhui Medical UniversityP2B (59)
Hydroxychloroquine
Prostate Cancer
Lionel.D.Lewis, MDP2B (59)
Rhgm-Csf
Prostate Cancer
University of Wisconsin, MadisonP2B (59)
IBUPROFEN
Prostate Cancer
Albany Medical CollegeP4B (58)
Abemaciclib
Prostate Cancer
OHSU Knight Cancer InstituteP3B (58)
Showing 51 to 75 of 427 assets
PreviousPage 3 of 18Next